Roche Holding AG (OTCMKTS:RHHBY) Receives Consensus Recommendation of “Hold” from Analysts

Roche Holding AG (OTCMKTS:RHHBY) has earned a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $45.71.

Several research analysts recently weighed in on the company. Morgan Stanley reiterated an “equal weight” rating on shares of Roche in a research report on Thursday, June 10th. Societe Generale reissued a “hold” rating on shares of Roche in a report on Tuesday, July 27th. Cowen assumed coverage on Roche in a report on Wednesday, July 21st. They issued an “outperform” rating on the stock. Barclays set a $46.42 price objective on Roche and gave the company an “overweight” rating in a report on Friday, July 23rd. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Roche in a report on Monday, August 2nd.

RHHBY stock traded up $0.11 during trading on Wednesday, hitting $46.86. 781,520 shares of the company traded hands, compared to its average volume of 1,501,570. The stock’s 50-day simple moving average is $48.82 and its 200 day simple moving average is $45.10. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.30 and a quick ratio of 1.01. The company has a market cap of $320.05 billion, a PE ratio of 17.64, a P/E/G ratio of 2.32 and a beta of 0.34. Roche has a 1 year low of $39.72 and a 1 year high of $51.05.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its position in Roche by 51.3% in the first quarter. ARK Investment Management LLC now owns 8,105,763 shares of the company’s stock valued at $328,770,000 after purchasing an additional 2,748,760 shares during the period. Parametric Portfolio Associates LLC raised its position in Roche by 5.2% in the second quarter. Parametric Portfolio Associates LLC now owns 6,189,665 shares of the company’s stock valued at $290,852,000 after purchasing an additional 307,919 shares during the period. Fisher Asset Management LLC raised its position in Roche by 67.9% in the second quarter. Fisher Asset Management LLC now owns 2,548,816 shares of the company’s stock valued at $120,137,000 after purchasing an additional 1,030,442 shares during the period. Saratoga Research & Investment Management raised its position in Roche by 45.8% in the second quarter. Saratoga Research & Investment Management now owns 1,106,075 shares of the company’s stock valued at $51,974,000 after purchasing an additional 347,533 shares during the period. Finally, Cullen Capital Management LLC raised its position in Roche by 23.4% in the second quarter. Cullen Capital Management LLC now owns 1,045,259 shares of the company’s stock valued at $49,117,000 after purchasing an additional 198,352 shares during the period. 0.32% of the stock is currently owned by institutional investors.

Roche Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process.

Further Reading: When can a hold rating present a buying opportunity?

Analyst Recommendations for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.